TITLE

CLINICAL EVALUATION OF VASCORAY

AUTHOR(S)
Marshall, T. R.
PUB. DATE
May 1973
SOURCE
Angiology;May1973, Vol. 24 Issue 5, p288
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
A clinical comparison and use of a new salt mixture of iothalamate�Vascoray (sodium iothalamate 26%/methylglucaminc iothalamate 52%)�with Conray (methylglucamine iothalamate 60%), Conray-400 (sodium iothalamate, 66.8%), Hypaque-M 75% (sodium diatrizoate 25%/methylglucamino diatrizoato 50%) and Angio-Conray (sodium iothalamate 80%) has been carried out. Tlie sodium solutions were found to produce more major and minor side effects, to have the lowest viscosity, and be more irritating to the myocardium, cerebral circulation, and spinal cord. The methylglucamine solutions had fewer side effects, but a greater viscosity for a similar iodine content. A combination of the sodium and methylglucamine salts of iothalamate and diatrizoate produced fewer side effects in the procedures compared, Table III. The iothalamate compound produced fewer side effects than the diatrizoate compared. Table III. Vascoray is a sterile solution of 400 mg of organically bound iodine per ml (40% iodine). Each ml contains 260 mg of sodium and 520 mg of methylglucamine as mixed salts of iothalamic acid and not more than 0.15 mg sodium biphosphate as a buffer. This compound was formulated because of the increasing need for an agent with fewer major and minor side effects for aortography and angiocardiography. It has a viscosity of 14.0 centipoises at 25�C, and 9.0 centipoises at 37.5�C. The intravenous LD50 (mice) for methylglucamine iothalamate 60% is 17,000 mg/kg; sodium iothalamate 66.8% is 19,000 mg/kg; sodium iothalamtitc 26%/methylglucamine iothalamate 52% is 18,000 mg/kg; and sodium iothalamate 80% is 21,000 mg/kg, Table I. Hayes has reported that all standardized toxicity studies comparing iothalamate preparations and diatrizoate preparations proved the iothalamate preparations to be less toxic than the diatrizoate preparations as regards neurotoxicity, nephrotoxicity and cardiopulmonary toxicity. Gensini has suggested that the methylglucamine salt may be safer than the sodium salt in the coronary arteries, myocardium and spinal cord tissues. Sodium salts are more toxic to the spinal cord, coronary arteries and myocardium than the methylglucamine salts. Methylglucamine salts are generally accepted as less toxic than sodium salts; however, they have a higher viscosity than sodium solutions. The combination of the two salts reduced the same effects while maintaining adequate flow rates, since the sodium solution has a lower viscosity and faster flow rate. This new agent combines the low toxicity-high viscosity of methylglucamine iothalamate with somewhat higher toxicity-lower viscosity of sodium iothalamate.
ACCESSION #
16353748

 

Related Articles

  • Innovation! Vaughan, Roger D. // American Journal of Public Health;Aug2008, Vol. 98 Issue 8, p1353 

    The article discusses various reports published within the issue, including one fractional factorial experimental designs and another on the design of more-efficient, longer-term randomized controlled trials and other data management and statistical techniques to help detect adverse drug events...

  • Underrecognition of adverse effects. Kuritzky, Louis // Alternative Medicine Alert;Aug2010 Supplement, p15 

    The article discusses research by M. Zimmerman published in the "Journal of Clinical Psychiatry" which investigated why adverse effects related to medication are usually undetected in clinical trials.

  • Identification of adverse reactions to new drugs. IV--Verification of suspected adverse reactions. Venning, Geoffrey R. // British Medical Journal (Clinical Research Edition);2/12/1983, Vol. 286 Issue 6364, p544 

    Examines the verification of suspected adverse reactions through the identification of adverse reactions to drugs in Great Britain. Characteristics of different methods of verification; Importance on the design of clinical trials of drugs; Assessment of the voluntary reporting systems.

  • Which AEs to collect for supplemental indications?  // Reactions Weekly;12/11/2010, Issue 1331, p3 

    The article discusses research being done on the gathering of adverse event (AE) data in cancer clinical trials, which references a study by L. D. Kaiser and colleagues in the October 4, 2010 issue of the "Journal of Clinical Oncology."

  • Pharmacovigilance & Regulatory News.  // Reactions Weekly;5/28/2011, Issue 1353, p2 

    The article reports on the draft guidance released by the Indian Central Drugs Standard Control Organization (CDSCO) in May 2011 geared toward the tightening of requirements for the reporting of serious adverse events occurring during clinical trials.

  • Lacosamide Doty, Pamela; Rudd, G. David; Stoehr, Thomas; Thomas, Dirk // Neurotherapeutics;Jan2007, Vol. 4 Issue 1, p145 

    Summary: Lacosamide is a new chemical entity being investigated as an adjunctive treatment for epilepsy, as well as monotherapy for diabetic neuropathic pain. Lacosamide appears to have a dual mode of action: selective enhancement of sodium channel inactivation and modulation of collapsin...

  • Dobutamine.  // Reactions Weekly;5/14/2011, Issue 1351, p21 

    The article describes the case of a 53-year-old woman who developed reversible cerebral vasoconstriction syndrome after receiving a dobutamine injection for stress testing.

  • Novel dry AMD treatment found safe, tolerable in phase 1b study.  // Ocular Surgery News;6/25/2012, Vol. 30 Issue 12, Special section p12 

    The article reports that according to a research involving phase 1b study by Ryo Kubota and colleagues, visual cycle modulator, is a safe and well-tolerated treatment for an oral dry age-related macular degeneration (AMD). It highlights that any ocular adverse events occurring during the...

  • GHTF drafts doc on trial adverse event reports. McCarty, Mark // Medical Device Daily;8/14/2012, Vol. 16 Issue 157, p8 

    The article reports on the draft document produced by the Global Harmonization Task Force (GHTF) that addresses reporting requirements for adverse events incurred during clinical trials under ISO 14155.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics